Introduction
B-RAF is the most commonly mutated driver oncogene in melanoma, with activating mutations in codon 600 occurring in almost 50% of the patients (1, 2) . Treatment with B-RAF selective inhibitors such as vemurafenib or dabrafenib, has demonstrated significant benefit in melanoma patients with B-RAF V600E mutation, with extended patient progression free survival and median overall survival compared with chemotherapy (3) (4) (5) (6) . However, these responses were relatively short-lived, and drug resistance generally developed within 5-7 months (4, 6) . Thus the emergence of resistance remains a considerable therapeutic challenge to achieve durable responses and prolonged survival in these patients.
A variety of molecular mechanisms are identified to be involved in resistance to B-RAF inhibition. The most common resistant mechanism is MAPK pathway reactivation, which is caused by genetic mutation of MEK or different Ras isoforms (7) (8) (9) , upstream activation of receptor tyrosine kinases (RTK) such as FGFR3 and c-Met (10, 11) , expression of B-RAF V600E splice variants that dimerize in presence of the B-RAF inhibitor (12) , amplification of B-RAF (13, 14) and upregulation of MAP3Ks such as COT or C-RAF (15, 16) . Alternatively, activation of MAPK-redundant pathways such as PI3K/Akt as a consequence of PTEN loss (17) , or overexpression of RTKs such as PDGFRβ and IGF1Rβ have also been reported to induce resistance in B-RAF V600E melanoma (7, 18, 19) . Additionally, secretion of growth factors such as HGF or FGF has also been implicated in resistance to B-RAF inhibition (10, 11, 20, 21) . Although the resistant mechanisms are frequently associated with MAPK reactivation, treatment with the MEK inhibitor trametinib, or with trametinib plus dabrafenib, has not been very effective in patients that have previously failed B-RAF inhibitor (22) , suggesting that subsequent targeting of MAPK signaling alone is not sufficient. Therefore, despite recent advances in the clinic, drug resistance upon selective B-RAF inhibition remains a considerable therapeutic challenge in clinic.
Constitutive activation of CDKs and deregulation of cell cycle are common features across several cancer types, including melanoma. P16 INK4a , a tumor suppressor gene and negative regulator of CDK4, is deleted in 38% of melanoma (2, 23) . In addition, germline mutations and amplification of 4 CDK4 gene have been identified in melanoma, which leads to unrestricted CDK4 activity and increased cell proliferation (2, 24) . In general, regulation of cell cycle entry in proliferating adult mammalian cells is controlled by D-cyclins which bind and activate CDK4 and CDK6, to promote phosphorylation of retinoblastoma (Rb) protein and G1-S transition (25) . The RAS-MAPK pathway is known to control cell cycle entry via upregulation of cyclin D1 in several cell types (26, 27) . Inhibition of MAPK signaling by B-RAF inhibitors decrease cyclin D1 expression and upregulate CDK inhibitor p27 KIP1 levels, thus blocking cell cycle entry in B-RAF V600E melanoma (26, 27) . Overexpression of cyclin D1 is linked to resistance to B-RAF inhibition (28) . Cyclin D1 is amplified in 11% of melanoma, including 17% of B-RAF V600E melanoma, thus suggesting a potential role of cyclin D1 in intrinsic resistance to B-RAF inhibitors (2, 28) . However, the role of cyclin D1 in acquired-resistance to vemurafenib has not been described, and the therapeutic value of targeting cyclin D1/Rb axis to overcome vemurafenib-resistance has not been explored.
In this study, we have generated multiple in vitro cell lines and an in vivo model of resistance to vemurafenib, and discovered that MAPK reactivation and cyclin D1 elevation are common in these resistant models. We describe that cyclin D1 is an important mediator of vemurafenib-resistance and provides a potential therapeutic target to overcome resistance to B-RAF inhibition in B-RAF V600E melanoma. Using these in-vitro and in-vivo models, we show that cyclin D1 is generally elevated, and functions as a critical node for the survival of vemurafenib-resistant cells. We further demonstrate that LY2835219, a selective dual CDK4/6 inhibitor currently in phase 2 clinic studies (29) , can overcome vemurafenib resistance in these resistant models. Altogether, this study sheds new light on mechanisms of resistance to B-RAF inhibition, identifies cyclin D1 elevation concurrent with MAPK reactivation as a common resistant mechanism, and proposes targeting cyclin D1 through CDK4/6 inhibition by LY2835219 as an effective therapeutic strategy to overcome B-RAF resistance. 
Materials and Methods
Cell culture, reagents and transfections-A375, SH4 and A2058 cells were obtained from ATCC on 5/7/12, 7/2/12, 6/27/06 respectively. M14 cells were purchased from NCI on 3/10/05. Cells were stored within a central cell bank that performs cell line characterizations. All these cells were passaged for fewer than 2 months after which time new cultures were initiated from vials of frozen cells. Characterization of the cell lines was done by a third party vendor (RADIL, Columbia, Missouri, USA, which included profiling (by PCR) for contamination by various microorganisms of bacterial and viral origin. As a result, no contamination was detected. The samples were also verified to be of human origin without mammalian inter-species contamination. The alleles for 9 different genetic markers were used to determine that the banked cells matched the genetic profile that has been previously reported.
All cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Thermo Scientific) supplemented with 10% fetal bovine serum (FBS, Invitrogen). B-RAF selective inhibitor vemurafenib and CDK4/6 dual inhibitor LY2835219 were synthesized by Eli Lilly and Company. The mesylate salt of LY2835219 (LY2835219.CH 4 O 3 S) was used in all the in vitro studies. All siRNAs were obtained from Dharamcon (OnTargetPlus SiRNA). SiRNA transfections were performed using Lipofectamine Cruz), GAPDH (Santa Cruz), tubulin (ab7291, AbCam), phospho-histone H3 (S10) (Millipore), phosphoRb (S780) (BD Biosciences) were obtained from the indicated companies.
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Generation of vemurafenib resistant cell lines -A375R1, A375R3, M14R and SH4R models with acquired-resistance to vemurafenib were generated by treating respective parental cells with gradually increasing concentrations of vemurafenib, up to 2 µM, as previously described (10) . A375R2 cells were generated by treating A375 cells with a high concentration of vemurafenib (2 µM) for 1 week, followed by culturing with vemurafenib (1 µM) for up to 20 passages. Upon establishment of resistance, the inhibitor was withdrawn and all of the cell lines were maintained in regular media for subsequent passages. For A375R4 cells, the NRas Q61K was stably transfected into A375 cells, and single cell clone was selected and characterized for this study. All of the models retained resistance to vemurafenib for up to 20 passages (data not shown). In this study, all resistant cell lines with less than 10 passages were utilized for experiments. 
Cell proliferation assay-

Results
Development of vemurafenib resistant cell lines-To study the resistant mechanisms of B-RAF inhibition, we generated several vemurafenib resistant cells outlined in Table 1. A375R1, A375R3, M14R and SH4R cells were generated by treating their respective parental cells with gradually increasing concentrations of vemurafenib, up to 2 µM as described previously (10) . The resistant mechanism of A375R1, A375R3 and M14R cells was associated with RTK/RAS activation and MAPK reactivation (10) . MAPK reactivation was also observed in SH4 cells, but the underlying mechanism has not been fully characterized. A375R2 cells were generated by treating A375 cells with a constant 2 µM vemurafenib as described (12) . Consistent with the earlier reports, the resistance of A375R2 cells to vemurafenib is conferred by expression of B-RAF splice variant (Supplementary S1A). The A375R4 cells were generated through stable transfection of NRas Q61K mutant and single clone selection, which resulted in vemurafenib resistance (Supplementary figure S1B).
MAPK reactivation and cyclin D1 elevation in vemurafenib resistant cells and their sensitivity to
CDK4/6 inhibitor LY2835219-As shown in table 1, all in vitro generated resistant cell lines, A375R1-R4, M14R and SH4R demonstrated resistance to vemurafenib. Importantly, these resistant cells showed enhanced MAPK activation and cyclin D1 elevation ( Figure 1 ). MAPK pathway activation and loss of cell cycle control are generally the hallmarks of melanoma (2) . Therefore, we used a selective CDK4/6 dual inhibitor LY2835219, and evaluated its growth inhibitory effects in a panel of melanoma cell lines that are either sensitive or resistant to vemurafenib mediated by diverse mechanisms (Table 1) .
Interestingly, B-RAF V600E melanoma cells that are either sensitive to vemurafenib, such as A375, M14 and SH4, or resistant to vemurafenib, such as A375R1-4, M14R and SH4R, demonstrated comparable sensitivity to LY2835219 with IC50s ranging from 0.3-0.6 µM, (Table 1) . On the contrary, BRAF V600E mutant A2058 cells with de novo resistance to vemurafenib via MAPK-independent mechanism (i.e PTEN deletion) was relatively insensitive to LY2835219 (Table 1) . Figure 3A , LY2835219 treated mice demonstrated significant tumor growth regression, whereas the tumors in vemurafenib-treated mice continued to grow. Furthermore, LY2835219 mediated tumor growth inhibition was maintained upon cessation of the treatment. To rule out the possibility that the tumors had developed a dependence on vemurafenib for continued growth as previously described (14), we repeated the same experiment with a vehicle control arm in addition to the continued vemurafenib arm and the LY2835219 treatment group. In this study both the vehicle control group and the vemurafenib group showed indistinguishable and continued growth post vemurafenib withdrawal (Supplementary figure S2) . These results suggest that CDK4/6 inhibitor LY283519 as a single agent is effective in overcoming vemurafenib resistance in this in vivo model. We further investigated the molecular mechanism behind increased sensitivity of resistant tumors to LY2835219. We found hyperelevated levels of phospho-ERK, phospho-MEK, cyclin D1 and phospho-Rb (S780, S807, S811) in these vemurafenib-resistant tumors, indicating upregulation of MAPK and CDK activity ( Figure 3B ). This observation is consistent with previous findings that upregulation of cyclin D1 was associated with Table 1 ). We further characterized these cells and found that phospho-MEK and phospho-ERK levels remained high in the resistant cells in the presence of vemurafenib concentrations as high as 3 µM compared with parental A375 cells where phospho-MEK and p-ERK were diminished at concentrations as low as 500nM ( Figure 4B and supplementary figure S3 ). In addition, we also detected expression of p61-B-RAF splice variant in the A375RV1 cells ( Figure 4B ), suggesting that one mechanism of resistance to vemurafenib in this cell line is likely due to alterations in B-RAF splicing. Consistent with the observations from the analysis of the tumor lysates, the cell lines derived from the resistant tumors also showed enhanced expression of cyclin D1 ( Figures 4B and S4C ). 
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Discussion
In this study, we generated multiple in vitro cell lines and an in vivo model resistant to vemurafenib, and discovered that MAPK reactivation and cyclin D1 elevation are associated with acquired resistance in these models. We further describe that inhibition of cyclin D1-CDK4/6 signaling by CDK4/6 inhibitor LY2835219 is an effective therapy to overcome resistance. Expression of B-RAF V600E splice variants, RTK/Ras activation, NRas mutation and B-RAF amplification are the predominant clinical mechanisms of resistance to vemurafenib that have been observed to date, and all of these resistant mechanisms together with BRAF mutation induce hyperactivation of MAPK pathway (7, 12, 13) . We found that the cells resistant to vemurafenib with hyperactivation of MAPK pathway have elevated cyclin D1 expression, and that they were sensitive to CDK4/6 inhibitor LY2835219.
We Both vemurafenib and LY2835219 were demonstrated to inhibit tumor growth of BRAF V600E melanoma in single agent, and combination of these two resulted in an additive tumor growth inhibition ( Figure 2 ). This suggests that upfront combination of CDK4/6 and B-RAF inhibitors may be more efficacious than single agent therapy. However, a more robust tumor growth regression was observed when CDK4/6 inhibitor LY2835219 was utilized for treatment of xenograft tumors acquired resistance to vemurafenib ( Figure 3A) . These results suggest that vemurafenib followed by LY2835219 treatment schedule might be a more effective approach than upfront combination of these two agents in delaying and overcoming resistance. Additional studies in defining these dose schedules are ongoing in preclinical models.
Previous studies revealed that cyclin D1 overexpressing cells demonstrate constitutive CDK activity, and increased sensitivity to CDK4/6 inhibitors (30, 31) . Cyclin D1 was also demonstrated to be implicated in resistance to inhibitors of ERBB2, EGFR and ER signaling (32, 33) . Recent studies suggest that cyclin D1 overexpression may be sufficient to render B-RAF V600E melanoma cells resistant to B-RAF inhibition (28) . CCND1 is amplified in 11% of melanoma (2), including 17% of B-RAF V600E melanoma (28) , indicating that it could be a mechanism of de novo resistance to B-RAF inhibitors.
Molecular analysis of our vemurafenib-resistant tumors revealed significant upregulation of cyclin D1 levels relative to parental tumors ( Figure 3B ). Consistently, cyclin D1 was also upregulated across most 
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cell line. However, in at least A375R1 case we found that the vemurafenib resistance was associated with 11q13 copy number gain (Table S1 ). This chromosomal region includes the genes for FGF ligands as well as CCND1, potentially explaining both the cyclin D1 upregulation and CDK4/6 dependence described here, as well as the previously reported FGF pathway activation (10) . Analysis of cyclin D1 amplification in other resistant cells is ongoing. We further investigated if cyclin D1 is required for proliferation and survival of vemurafenib-resistant cells. Consistent with the pro-apoptotic effects of LY2835219, knockdown of cyclin D1 by shRNA also induced higher levels of apoptosis in vemurafenib-resistant vs parental cells ( Figure 6B and supplementary figure S4C ). However, these data do not entirely exclude the possibility that either off-target effects of LY2835219 or inhibition of Rb-independent pathways by cyclin D1 knockdown might also contribute to the induction of apoptosis observed selectively in vemurafenibresistant cells. Altogether, we demonstrate that cyclin D1 is important for survival of vemurafenibresistant cells with hyperactivation of MAPK pathway and cyclin D1 upregulation, and propose LY2835219, a CDK4/6 dual inhibitor as a potential therapy to overcome such resistance. 
